NCT07885956
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Percentage of participants reporting local reactions
Timeframe: For up to 7 days after vaccination
Percentage of participants reporting systemic events
Timeframe: For up to 7 days after vaccination
Percentage of participants reporting adverse events
Timeframe: Through 1 month after vaccination
Percentage of participants reporting newly diagnosed chronic medical conditions
Timeframe: Through 18 months after vaccination
Percentage of participants reporting serious adverse events
Timeframe: Through 18 months after vaccination
Arms and interventions
Group 1Experimental
Participants will receive a single open-label, intramuscular injection of RSVpreF (Regimen A) as a revaccination.
Group 2Experimental
Participants will receive a single open-label, intramuscular injection of RSVpreF (Regimen B) as a revaccination.
Group 3No intervention
Participants will not be revaccinated.
Biologicals: RSVpreF (Regimen A), RSVpreF (Regimen B)